Clinical Competition Candidate

TROKENDI XR

TROKENDI XR carries product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 21 months away. Active clinical competition may compress the generic entry window.

Back to watchlist Contact us about this drug

LOE window

21months

to latest listed patent expiry (April 4, 2028)

Expiry attractiveness: 5/5

Patent profile

Substance patent (none)

Product / formulation patent (listed)

Use-code patent (listed)

Patent count: 20

Complexity score: 3/5

Clinical competition

Score: 5/5

Active trials linked: 300

Phase 2/3 trials: 135

Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.

Drug overview

Active ingredient: TOPIRAMATE

Applicant (NDA holder): SUPERNUS PHARMACEUTICALS INC

Confidence: High